Engineers Gate Manager’s Arcturus Therapeutics ARCT Stock Holding History

Engineers Gate Manager’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$193K	Sell	28,768 -17,065	-37%	-$135K	﹤0.01%	1967
2026 Q1	$354K	Sell	45,833 -22,347	-33%	-$163K	﹤0.01%	1620
2025 Q4	$418K	Buy	+68,180	New	+$736K	0.01%	1450
2023 Q3	–	Sell	-17,612	Closed	-$505K	–	1780
2023 Q2	$505K	Buy	17,612 +7,222	+70%	+$197K	0.02%	1029
2023 Q1	$249K	Buy	+10,390	New	+$186K	0.01%	1340
2021 Q3	–	Sell	-29,749	Closed	-$1.01M	–	1624
2021 Q2	$1.01M	Buy	29,749 +13,024	+78%	+$441K	0.06%	441
2021 Q1	$691K	Buy	16,725 +6,208	+59%	+$370K	0.03%	799
2020 Q4	$456K	Buy	+10,517	New	+$712K	0.02%	1037
2020 Q3	–	Sell	-16,164	Closed	-$756K	–	1655
2020 Q2	$756K	Sell	16,164 -6,252	-28%	-$215K	0.04%	731
2020 Q1	$305K	Buy	+22,416	New	+$287K	0.02%	1029
2019 Q4	–	Sell	-13,043	Closed	-$134K	–	1604
2019 Q3	$134K	Buy	+13,043	New	+$141K	0.01%	1268

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Engineers Gate Manager's ARCT Position: Q2 2026 in Review

Engineers Gate Manager reduced its Arcturus Therapeutics (ARCT) stake by 37% in Q2 2026, selling an estimated $135K and leaving 28,768 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #1967.

Engineers Gate Manager first reported a position in ARCT in Q3 2019 and has held it in 11 quarters since. The position peaked at $1.01M in Q2 2021. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Engineers Gate Manager held 28,768 shares of Arcturus Therapeutics worth $193K as of Q2 2026.
Engineers Gate Manager sold 17,065 Arcturus Therapeutics shares in Q2 2026, an estimated $135K.
Arcturus Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1967 holding.
Engineers Gate Manager first reported a position in Arcturus Therapeutics in Q3 2019 and has held it in 11 quarters since.
Engineers Gate Manager's Arcturus Therapeutics position peaked at $1.01M in Q2 2021.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.